Ratings Charlotte's Web Holdings Inc Canadian Securities Exchange

Equities

CWEB

CA16106R1091

Delayed Canadian Securities Exchange Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		-1.63%	+27.22%

Mar. 21	Transcript : Charlotte's Web Holdings, Inc., Q4 2023 Earnings Call, Mar 21, 2024
Mar. 21	Charlotte's Web Holdings Narrows Q4 Loss, Revenue Falls	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Over the past four months, analysts' average price target has been revised downwards significantly.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CHARLOTTE'S WEB HOLDINGS INC	+27.22%	29.86M		-
DONG-E-E-JIAO CO.,LTD.	+35.04%	5.92B		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B		C+
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B		B-
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B		C
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B	-	D+
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B		-
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B	-	-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B	-	-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes